Bacterial Infections

The STI & HIV World Congress is the leading global forum on sexually transmitted infections (STIs), HIV, and sexual health. Jointly organized by the International Society for Sexually Transmitted Diseases Research (ISSTDR)  and the International Union Against Sexually Transmitted Infections (...

Dr Darius Hareza (Northwestern University, Chicago, USA) discusses major developments from IDWeek 2025, including the alarming rise in NDM-producing Enterobacterales, the approval of gepotidacin for gonorrhoea, and spirited debates around daptomycin versus vancomycin and new UTI treatment durations.

In this Q&A, Jarod Hanson, Chief Content Office of ProMED, in affiliation with ISID, discuss how the ProMED platform continues to empower clinicians and epidemiologists worldwide, its evolving integration of AI, and how new partnerships aim to extend its reach into low-resource settings to strengthen the global early warning system.

Bacterial vaginosis (BV) remains one of the most common vaginal infections worldwide, yet accurate diagnosis continues to challenge clinicians. In this expert interview, Dr Olivia Van Gerwen (University of Alabama at Birmingham) explores the limitations of current diagnostic tools, the impact of misdiagnosis and how advances in molecular and point-of-care testing could transform women’s sexual health practice.

In our inaugural touchINFECTIOUS DISEASES Future Leaders 2025 campaign, we celebrate early-career clinicians and researchers whose innovation, leadership, and curiosity are already shaping better outcomes in patient care, antimicrobial stewardship, and global health.

In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.

TNX 4800, a first-in-class, single-dose monoclonal antibody being developed as a seasonal prophylactic, akin to a ‘Lyme vaccine’, for the prevention of Lyme disease, has been had in-licencing announced. Designed for springtime administration, TNX 4800 provides passive immunity against Borrelia burgdorferi, the causative agent of Lyme disease, offering protection throughout the United States tick season.

Bacteriophage therapy uses viruses to infect and kill harmful bacteria, and is re-emerging as a powerful tool in the fight against multidrug-resistant infections. Once overshadowed by the discovery of antibiotics, this highly targeted treatment is now gaining global attention as antibiotic resistance continues to rise. In this Q&A, Ikechukwu Moses (Division of Infectious Diseases, EPM-UNIFESP, São Paulo, Brazil, explores how phage therapy works, its clinical applications, and what’s needed to bring it into mainstream infectious disease care.

Infectious disease diagnostics are at the forefront of tackling global health challenges. Research Fellow and PhD candidate Prerna S. Salian shares her journey from microbiology to pioneering faster sepsis detection, and her vision for integrating next-generation sequencing with AI to transform patient care.